750P PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial

Brian M Slomovitz ,Sharad Ghamande ,Orlando Doehring ,Nicoline Raaschou‐Jensen ,Destin Black ,Lyndsay Willmott ,Thomas J Herzog ,Matthew A Powell ,Beyhan Ataseven ,Lucy Gilbert ,Machteld Wymenga ,David Cibula ,Carolyn K Mccourt ,Iwona Podzielinski ,Laura Zavallone ,Alberto A Mendivil ,Robert L Coleman ,Jamie Garside ,Caroline C Billingsley ,Mansoor Raza Mirza

doi:10.1016/j.annonc.2023.09.1929

750P PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial

Brian M Slomovitz , Sharad Ghamande + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2023.09.1929

Copy DOI

#Anticancer Therapy In Patients #Recurrent Endometrial Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

750P PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial

Full Text